| Literature DB >> 35463742 |
Yunling Xuan1,2, Chen Chen1,2, Zheng Wen1,2, Dao Wen Wang1,2.
Abstract
In myocarditis caused by various etiologies, activated immune cells and the immune regulatory factors released by them play important roles. But in this complex microenvironment, non-immune cells and non-cardiomyocytes in the heart, such as cardiomyocytes (CMs), cardiac fibroblasts (CFs) and endothelial cells (ECs), play the role of "sentinel", amplify inflammation, and interact with the cardiomyocytes. The complex interactions between them are rarely paid attention to. This review will re-examine the functions of CFs and ECs in the pathological conditions of myocarditis and their direct and indirect interactions with CMs, in order to have a more comprehensive understanding of the pathogenesis of myocarditis and better guide the drug development and clinical treatment of myocarditis.Entities:
Keywords: cardiac fibroblasts; cross-talk; endothelial cells; extracellular vesicles; myocarditis
Year: 2022 PMID: 35463742 PMCID: PMC9022788 DOI: 10.3389/fcvm.2022.882027
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Figure 1Fibroblast and endothelial cell activation. Fibroblasts are activated in viral infection or in the environment containing cytokines. Then they produce pro-inflammatory factors and chemokines such as TNF-α, IL-6, MCP-1, IFN-β, CCL11, CCL12. They can also produce MMP family proteins to regulate cardiac interstitial fibrosis. Under the stimulation of these microenvironments, endothelial cells produce adhesion molecules to regulate the adhesion and infiltration of inflammatory cells. The participation of fibroblasts and endothelial cells promotes more severe cardiac inflammatory infiltration and more severe fibrosis.
Figure 2Fibroblasts, endothelial cells and cardiomyocytes interaction diagram. Fibroblasts, endothelial cells can interact with cardiomyocytes through mechanical coupling and electrical coupling. They also act through paracrine effects and/or cell-secreted vesicles or exosomes. Cardiomyocytes secrete pro-inflammatory factors such as TNF-α, IL-1β, and IL-6 through paracrine effects to act on fibroblasts, and they can also deliver intracellular miRNAs through exosomes, such as miR92a, miR195, and miR378. These mediators can affect fibroblast proliferation, migration, differentiation and matrix production. Fibroblasts can also secrete factors such as TGF-β through paracrine action or deliver miRNAs into cardiomyocytes through exosomes, which affect cardiomyocyte contraction and cardiac hypertrophy. Similarly, endothelial cells can secrete effector molecules such as IL-8 through paracrine effects, and can also carry ROS through exosomes, thereby affecting various functions of cardiomyocytes. In contrast, cardiomyocytes can affect endothelial cell migration, proliferation, and angiogenesis by secreting exosomes carrying molecules such as miR-21.
Table of CF-CM and CM-CF interactions in the cardiovascular field.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Heart development | CF-CM | Paracrine | – | CMs are specialized as ventricular conduction system-like cells, CNMs maturation | ( |
| Heart failure caused by TAC | CM-CF | Paracrine | IL-6 | CFs migration, proliferation, and myofibroblast differentiation | ( |
| CM-CF | Extracellular vesicles | miR-378 | CFs proliferation, fibrosis | ( | |
| CM-CF | Paracrine | β2 microglobulin | CFs activation | ( | |
| MI | CM-CF | Extracellular vesicle | miR-92a | Myofibroblast activation | ( |
| – | CM-CF | Exosomes | miR-195 | Myofibroblast activation | ( |
| CF-CM | Paracrine | TGF-β | CMs hypertrophy | ( | |
| DOX-induced cardiotoxicity | CF-CM | Paracrine | FGF2 | CMs damage | ( |
| Early hypoxia | CM-CF | Paracrine | TNF-α, IL-1β | CFs migration | ( |
| Ang II-induced cardiac hypertrophy | CF-CM | Exosomes | miR-21-3p | CMs hypertrophy | ( |
| H/R | CF-CM | Paracrine | TIMPs-1 | CMs viability | ( |
| CF-CM | Exosomes | miR-423-3p | CMs viability and apoptosis | ( | |
| CM-CF | Paracrine | Polycystin-1 | CFs differentiate, profibrotic factors expression | ( |
–, No specific information is given in the original text.
TAC, transverse aortic constriction; MI, myocardial infarction; DOX, Doxorubicin; FGF2, fibroblast growth factor 2; H/R, Hypoxia–reoxygenation; Ang II, angiotensin II; Gal-3, Galectin-3; sFRP2, Secreted frizzled-related protein 2.
Table of EC-CM and CM-EC interactions in the cardiovascular field.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| ET-1 pre-stimulated ECs | EC-CM | Paracrine | – | CMs hypertrophy | ( |
| Hypoxic ECs | EC-CM | Paracrine | TGFβ1 | CMs apoptosis | ( |
| H/R | EC-CM | Paracrine | SLPI | CMs damage | ( |
| EC-CM | Microvesicles (MVs) | ROS | CMs apoptosis and oxidative stress | ( | |
| OGD | CM-EC | Exosomes | miR-21 | Angiogenic activity | ( |
| Ischemic preconditioning | EC-CM | Exosomes | – | CMs activity | ( |
| – | hiPSC-CM -EC | Exosomes | miR-21-3p | Angiogenesis, ECs migration and proliferation | ( |
| LPS | EC-CM | Exosomes | – | CMs damage | ( |
| DCM | EC-CM | Paracrine | NRG-1 | CMs contractility | ( |
| Hypercholesterolemia | EC-CM | Paracrine | Lipopolysaccharide-induced chemokine (LIX) and IL-8 | CMs apoptosis, Expression of the proinflammatory cytokines | ( |
–, No specific information is given in the original text.
ET-1, endothelin-1; SLPI, Secretory leukocyte protease inhibitor; ROS, Reactive Oxygen Species; OGD, Oxygen–glucose-deprivation; hiPSC-CM, Human induced pluripotent stem cell-derived cardiomyocytes; LPS, Lipopolysaccharide; NRG-1, Neuregulin-1.